SCOPUS 정보 검색 플랫폼

Statistics in Medicine

Volumn 20, Issue 14, 2001, Pages 2079-2090

Patient specific dosing in a cancer phase I clinical trial

(2) Babb, James S a Rogatko, André a

a FOX CHASE CANCER CENTER (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; NACOLOMAB TAFENATOX;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EXPOSURE; DRUG METABOLISM; DRUG RESEARCH; DRUG SPECIFICITY; DRUG TARGETING; DRUG TOLERANCE; GASTROINTESTINAL CARCINOMA; HUMAN; MAXIMUM TOLERATED DOSE; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; STATISTICAL ANALYSIS; STATISTICAL MODEL;

ADENOCARCINOMA; ANTIBODIES; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL NEOPLASMS; HUMANS; RESEARCH DESIGN; STATISTICS;

EID: 0035974284 PISSN: 02776715 EISSN: None Source Type: Journal
DOI: 10.1002/sim.848 Document Type: Article

Times cited : (75)

References (15)

1
- 0010480119
- Academic Press: New York
- (1979) Methods of Cancer Research
- Wooley, P.V.¹ Schein, P.S.²

2
- 0031920799
- Cancer phase I clinical trials: Efficient dose escalation with overdose control
- (1998) Statistics in Medicine , vol.17 , Issue.10 , pp. 1103-1120
- Babb, J.¹ Rogatko, A.² Zacks, S.³

3
- 0026924531
- Phase I cancer trials: Limitations and implications
- (1992) Molecular Biotherapy , vol.4 , Issue.3 , pp. 117-121
- Dillman, R.O.¹ Koziol, J.A.²

4
- 0025353690
- Responses and toxic deaths in phase I clinical trials
- (1990) Annals of Oncology , vol.1 , Issue.3 , pp. 175-181
- Decoster, G.¹ Stein, G.² Holdener, E.E.³

5
- 0027524863
- Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents
- (1993) Journal of National Cancer Institute , vol.85 , pp. 1637-1643
- Ratain, M.J.¹ Mick, R.² Schilsky, R.L.³ Siegler, M.⁴

6
- 0025360796
- Pharmacologically guided phase I clinical trials based upon preclinical drug development
- (1990) Journal of the National Cancer Institute , vol.82 , Issue.16 , pp. 1321-1326
- Collins, J.M.¹ Grieshaber, C.K.² Chabner, B.A.³

7
- 0029919926
- Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender
- (1996) Pharmacogenetics , vol.6 , Issue.1 , pp. 93-101
- Ratain, M.J.¹ Mick, R.² Janisch, L.³ Berezin, F.⁴ Schilsky, R.L.⁵ Vogelzang, N.J.⁶ Kut, M.⁷

8
- 0028354657
- Pharmacologically based phase I trials in cancer chemotherapy
- (1994) Hematology-Oncology Clinics of North America , vol.8 , Issue.2 , pp. 257-275
- Newell, D.R.¹

9
- 0027499297
- Model-guided determination of maximum tolerated dose in phase I clinical trials: Evidence for increased precision
- (1993) Journal of the National Cancer Institute , vol.85 , pp. 217-222
- Mick, R.¹ Ratain, M.J.²

10
- 0032978158
- Two-sample continual reassessment method
- (1999) Journal of the Biopharmaceutical Statistics , vol.9 , Issue.1 , pp. 17-44
- O'Quigley, J.¹ Shen, L.Z.² Gamst, A.³

11
- 0029780751
- Improved designs for dose escalation studies using pharmacokinetic measurements
- (1996) Statistics in Medicine , vol.15 , pp. 1605-1618
- Piantadosi, S.¹ Liu, G.²

12
- 0025148278
- Continual reassessment method: A practical design for phase I clinical trials in cancer
- (1990) Biometrics , vol.46 , pp. 33-48
- O'Quigley, J.¹ Pepe, M.² Fisher, L.³

13
- 0029155989
- Dose-response models with covariates
- (1995) Biometrics , vol.51 , Issue.3 , pp. 977-987
- Wijesinha, M.C.¹ Piantadosi, S.²

14
- 0000009450
- Sequential search of an optimal dosage I
- (1973) Journal of the American Statistical Association , vol.68 , pp. 594-598
- Eichhorn, B.H.¹ Zacks, S.²

15
- 0032525496
- Optimal Bayesian-feasible dose escalation for cancer phase I clinical trials
- (1998) Statistics and Probability Letters , vol.38 , pp. 215-220
- Zacks, S.¹ Rogatko, A.² Babb, J.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.